Home › Compare › AMYZF vs ABBV
AMYZF yields 3636.36% · ABBV yields 3.06%● Live data
📍 AMYZF pulled ahead of the other in Year 1
Combined, AMYZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AMYZF + ABBV for your $10,000?
RecycLiCo Battery Materials Inc. engages in the acquisition, exploration, and development of interests in mineral resource projects in Canada and the United States. It is also involved in the research and development of recycling battery cathode waste in lithium-ion batteries. The company explores for manganese, gold, silver, copper, cobalt, tungsten, and niobium deposits. It owns 100% interests in the Rocher Deboule property covering an area of approximately 1,441 hectares located in British Columbia; and the Lonnie property, which covers approximately 674 hectares located in British Columbia. The company also has interests in the Artillery Peak project comprising 30 unpatented mineral claims covering approximately 600 acres, and 13 patented surface estates located in Arizona. The company was formerly known as American Manganese Inc. and changed its name to RecycLiCo Battery Materials Inc. in October 2022. RecycLiCo Battery Materials Inc. was incorporated in 1987 and is headquartered in Surrey, Canada.
Full AMYZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.